

A Phase III Study of Deuremidevir Hydrobromide for the Treatment of RSV Infection in Infants and Young Children

NCT07402512

Status	RECRUITING
Phase	Phase 3
Sponsor	Simcere Pharmaceutical Co., Ltd
Enrollment	498 participants

Key Eligibility Criteria

Inclusion (7)

- Infants and young children aged e 1 month and d 36 months, regardless of gender;
- Weight e 2.5 kg and d 20 kg;
- Positive RSV antigen or nucleic acid test
- Duration of illness due to RSV infection d 96 hours;
- Presence of tachypnea and wheezing;
- ... and 2 more (see full listing online)

Exclusion (19)

- Subjects who have received protocol-speci ed prohibited medications;
- Subjects with severe intrapulmonary complications or extrapulmonary complications;
- Subjects requiring vasopressors or inotropic agents;
- Subjects with known concurrent SARS-CoV-2 infection, in uenza virus infection, Mycoplasma infection, or suspected concurrent bacterial or other pathogen infections;
- Subjects with a known history of hypercapnia;
- ... and 14 more (see full listing online)

Locations (4 total)

The First Affiliated Hospital Of Xiamen University, Xiamen, Fujian, China
Hunan Children's Hospital, Changsha, Hunan, China
West China Second University Hospital Sichuan University, Chengdu, Sichuan, China
... and 1 more locations